Portugal
China dominates new tests in innovative therapies with CAR-T cells
Publication: PÚBLICO
Author: publico@publico.pt
Source published: 29/09/2026, 11:04:00 UTC
Briefing created: 29/09/2026, 23:49:35 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/09/2026, 11:20:24 UTC.
Briefings
Recent data indicates China is conducting 82% of preclinical animal trials for innovative CAR-T therapies, despite the majority of human trials occurring in Europe and the United States. This shift reflects China's significant investment in biotechnology infrastructure during the 2026 period, though specific patient outcomes or regulatory approvals remain unconfirmed.
Key points
- China conducts 82% of preclinical animal trials for innovative CAR-T therapies, while human trials are predominantly located in Europe and the United States.
Context and limitations
Data covers only preclinical animal studies conducted in 2026; human clinical trial outcomes and regulatory approvals are not included in this snapshot.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/09/2026, 23:49:35 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigvfl2paz4z6a2lmefrs4ig5uwtmyh6zz7ia4wxutppfidwtyilye